FDA clears drug-coated stent from Abbott

07/2/2008 | Wall Street Journal, The · Bloomberg

The FDA on Wednesday approved Abbott Laboratories' Xience V drug-coated stent, which is expected to compete with Boston Scientific's Taxus and Johnson & Johnson's Cypher in the approximately $2 billion U.S. market for the devices. The clearance also allows Boston Scientific to launch Promus, a version of the Abbott-made stent.

View Full Article in:

Wall Street Journal, The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX